Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.

INO-3107 At The Crossroads: FDA Review Drives Inovio's Upside And Risk

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Shares of Inovio Pharmaceuticals Inc. INO advanced 3.31% to $1.56 Thursday, on what proved to be an all-around positive ...

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

This was the stock's second consecutive day of losses.
Morningstar

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...